Cargando…
The prognostic value of [(18)F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
PURPOSE: To investigate the prognostic value of [(18)F]FDG PET/CT as part of response monitoring in metastatic melanoma patients treated with immune checkpoint inhibitors (ICIs). METHODS: Sixty-seven patients underwent [(18)F]FDG PET/CT before start of treatment (baseline PET/CT), after two cycles (...
Autores principales: | Sachpekidis, Christos, Weru, Vivienn, Kopp-Schneider, Annette, Hassel, Jessica C., Dimitrakopoulou-Strauss, Antonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317882/ https://www.ncbi.nlm.nih.gov/pubmed/37099131 http://dx.doi.org/10.1007/s00259-023-06243-y |
Ejemplares similares
-
Can physiologic colonic [(18)F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
por: Sachpekidis, Christos, et al.
Publicado: (2023) -
Application of the long axial field-of-view PET/CT with low-dose [(18)F]FDG in melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2022) -
Assessment of early metabolic progression in melanoma patients under immunotherapy: an (18)F-FDG PET/CT study
por: Sachpekidis, Christos, et al.
Publicado: (2021) -
The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021) -
Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)